Individual patient risk assessment and cost–benefit analysis of patiromer in AMBER – Authors' reply
- 1 August 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 396 (10247), 311-312
- https://doi.org/10.1016/s0140-6736(20)30534-1
Abstract
No abstract availableFunding Information
- Gilead Sciences
- Boehringer Ingelheim
- Celgene
- Eli Lilly and Company
- Takeda Pharmaceuticals U.S.A.
- National Institutes of Health
- Sandoz
- U.S. Department of Veterans Affairs
- Daiichi-Sankyo
- Sanofi
This publication has 2 references indexed in Scilit:
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet, 2019
- Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER StudyAmerican Journal of Nephrology, 2018